Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PfSPZ-GA1
- Development stage
- Phase 1
- Lead developer
- Sanaria
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
PfSPZ-GA1 is a genetically attenuated, live malaria vaccine candidate composed of purified, aseptic, cryopreserved Plasmodium falciparum (NF54 strain) sporozoites. These sporozoites are genetically engineered by deletion of the b9 and slarp genes, which arrests parasite development in the early liver stage and prevents progression to blood-stage infection. The vaccine is administered via direct venous inoculation and aims to induce protective immunity against malaria by stimulating both humoral (anti-circumsporozoite protein antibodies) and cellular (interferon-γ–producing T cells) immune responses. Clinical trials have demonstrated that PfSPZ-GA1 is safe and immunogenic in malaria-naïve adults but has shown suboptimal protective efficacy so far. The developer is Sanaria, with ongoing clinical evaluation for use as a prophylactic vaccine against malaria[1][2][3][5].
- Brand names
- Sanaria PfSPZ-GA1
- Other names
- Pf∆b9∆slarpgenetically attenuated Plasmodium falciparum sporozoite vaccine
Beyond the preview
Go deeper on PfSPZ-GA1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PfSPZ-GA1.